Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Rachel E. Haurwitz net worth and biography

Rachel Haurwitz Biography and Net Worth

Co-Founder of Caribou Biosciences

Rachel is a co-founder of Caribou Biosciences and has been its President and Chief Executive Officer and a director since the company’s inception in 2011. Rachel is an inventor on patents and patent applications covering multiple CRISPR-based technologies, and has co-authored several scientific papers in high-impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. She serves on the board of directors of Seer, Inc. and the Biotechnology Innovation Organization (BIO). Rachel earned an A.B. in Biological Sciences from Harvard College and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

How old is Rachel E. Haurwitz?: Dr. Haurwitz is currently 38 years old. There are 5 older executives and no younger executives at Caribou Biosciences. The oldest executive at Caribou Biosciences is Ms. Barbara G. McClung Esq., J.D., Chief Legal Officer & Corporate Secretary, who is 69 years old. Learn More on Rachel E. Haurwitz's age.
How do I contact Rachel E. Haurwitz?: The corporate mailing address for Dr. Haurwitz and other Caribou Biosciences executives is , , . Caribou Biosciences can also be reached via phone at 510-982-6030 and via email at [email protected]. Learn More on Rachel E. Haurwitz's contact information.
Has Rachel E. Haurwitz been buying or selling shares of Caribou Biosciences?: Rachel E. Haurwitz has not been actively trading shares of Caribou Biosciences during the past quarter. Learn More on Rachel E. Haurwitz's trading history.
Who are Caribou Biosciences' active insiders?: Caribou Biosciences' insider roster includes Ryan Fischesser (VP), Rachel Haurwitz (Co-Founder), Steven Kanner (Insider), and Barbara McClung (Insider). Learn More on Caribou Biosciences' active insiders.

Rachel E. Haurwitz Insider Trading History at Caribou Biosciences

Rachel E. Haurwitz Buying and Selling Activity at Caribou Biosciences

Caribou Biosciences Company Overview

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Today's Range

Now: $4.07

$4.03

$4.39

50 Day Range

MA: $6.05

$4.07

$8.26

2 Week Range

Now: $4.07

$3.44

$8.59

Volume

1,609,048 shs

Average Volume

1,647,812 shs

Market Capitalization

$367.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.48